ERBB2 and gastric cancer: Additional immunohistochemical evaluations relevant to gastric cancer revealed that the tumor cells were Claudin 18.2 (CLDN18.2)-positive (Figure 3), HER2-negative, and mismatch repair (MMR)-proficient.